Send to

Choose Destination
J Med Chem. 2016 Jul 14;59(13):6387-406. doi: 10.1021/acs.jmedchem.6b00609. Epub 2016 Jun 28.

Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.

Author information

Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy.
Department of Pharmacy, University of Parma , Parco Area delle Scienze 27/A, 43124 Parma, Italy.
Department for Life Quality Studies, Alma Mater Studiorum University of Bologna , Corso d'Augusto 237, 47921 Rimini, Italy.
Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council , Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy.


The modulation of the endocannabinoid system is emerging as a viable avenue for the treatment of neurodegeneration, being involved in neuroprotective and anti-inflammatory processes. In particular, indirectly enhancing endocannabinoid signaling to therapeutic levels through FAAH inhibition might be beneficial for neurodegenerative disorders such as Alzheimer's disease, effectively preventing or slowing the progression of the disease. Hence, in the search for a more effective treatment for Alzheimer's disease, in this paper, the multitarget-directed ligand paradigm was applied to the design of carbamates able to simultaneously target the recently proposed endocannabinoid system and the classic cholinesterase system, and achieve effective dual FAAH/cholinesterase inhibitors. Among the two series of synthesized compounds, while some derivatives proved to be extremely potent on a single target, compounds 9 and 19 were identified as effective dual FAAH/ChE inhibitors, with well-balanced nanomolar activities. Thus, 9 and 19 might be considered as new promising candidates for Alzheimer's disease treatment.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center